{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:09:22Z","timestamp":1788826162346,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00521-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:25:23Z","timestamp":1782199523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ischemic heart disease and cardio-onco-hematology: a comprehensive review"],"prefix":"10.1186","volume":"12","author":[{"given":"Santiago","family":"Jim\u00e9nez-Marrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herminio","family":"Morillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Pons-Riverola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Ramos-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Berdejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Encarnaci\u00f3n","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Enjuanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Com\u00edn-Colet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moliner Borja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"521_CR1","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1161\/CIR.0000000000000641","volume":"139","author":"U Campia","year":"2019","unstructured":"Campia U, Moslehi J, Amiri-Kordestani L, Barac A, Beckman JA, Fadol A, et al. Cardio-Oncology: Vascular and Metabolic Perspectives. A Scientific Statement from the American Heart Association. Circulation. 2019;139:e579\u2013602.","journal-title":"Circulation"},{"issue":"9387","key":"521_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(03)14338-3","volume":"362","author":"M Ezzati","year":"2003","unstructured":"Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362(9387):847\u201352.","journal-title":"Lancet"},{"key":"521_CR3","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1093\/eurheartj\/ehae047","volume":"45","author":"P Ameri","year":"2024","unstructured":"Ameri P, Bertero E, Lombardi M, Porto I, Canepa M, Nohria A, et al. Ischaemic heart disease in patients with cancer. Eur Heart J. 2024;45:1209\u201323.","journal-title":"Eur Heart J"},{"key":"521_CR4","first-page":"365","volume":"37","author":"J Herrmann","year":"2019","unstructured":"Herrmann J. Common Vascular Toxicities of Cancer Therapies. Cardiol Clin. 2019;37:365\u201384.","journal-title":"Cardiol Clin"},{"issue":"6","key":"521_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.recesp.2018.12.011","volume":"72","author":"S Raposeiras Roubina","year":"2019","unstructured":"Raposeiras Roubina S, Cordero A. La relaci\u00f3n bidireccional entre el c\u00e1ncer y la ateroesclerosis. Rev Esp Cardiol. 2019;72(6):487\u201394.","journal-title":"Rev Esp Cardiol"},{"issue":"12","key":"521_CR6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/cac2.12357","volume":"42","author":"H Tu","year":"2022","unstructured":"Tu H, Ye Y, Huang M, Xie K, Chow WH, Zhao H, Wu X. Smoking, smoking cessation, and survival after cancer diagnosis in 128,423 patients across cancer types. Cancer Commun (Lond). 2022;42(12):1421\u20134.","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"521_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/1878-0261.12772","volume":"15","author":"CM Friedenreich","year":"2021","unstructured":"Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol. 2021;15(3):790\u2013800.","journal-title":"Mol Oncol"},{"issue":"5","key":"521_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/CIRCRESAHA.118.312669","volume":"124","author":"CJ Lavie","year":"2019","unstructured":"Lavie CJ, Ozemek C, Carbone S, Katzmarzyk PT, Blair SN. Sedentary Behavior, Exercise, and Cardiovascular Health. Circ Res. 2019;124(5):799\u2013815.","journal-title":"Circ Res"},{"key":"521_CR9","doi-asserted-by":"publisher","first-page":"291546","DOI":"10.1155\/2013\/291546","volume":"2013","author":"G De Pergola","year":"2013","unstructured":"De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.","journal-title":"J Obes"},{"issue":"8","key":"521_CR10","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/eurjpc\/zwae025","volume":"31","author":"A Welsh","year":"2024","unstructured":"Welsh A, Hammad M, Pi\u00f1a IL, Kulinski J. Obesity and cardiovascular health. Eur J Prev Cardiol. 2024;31(8):1026\u201335.","journal-title":"Eur J Prev Cardiol"},{"key":"521_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1475-2891-3-19","volume":"3","author":"MS Donaldson","year":"2004","unstructured":"Donaldson MS. Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr J. 2004;3:19.","journal-title":"Nutr J"},{"issue":"8","key":"521_CR12","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.3390\/nu13082623","volume":"13","author":"C Tang","year":"2021","unstructured":"Tang C, Wang X, Qin LQ, Dong JY. Mediterranean Diet and Mortality in People with Cardiovascular Disease: A Meta-Analysis of Prospective Cohort Studies. Nutrients. 2021;13(8):2623.","journal-title":"Nutrients"},{"key":"521_CR13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","volume":"373","author":"M Tancredi","year":"2015","unstructured":"Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbj\u00f6rnsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"521_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12916-024-03430-y","volume":"22","author":"WC Chang","year":"2024","unstructured":"Chang WC, Hsieh TC, Hsu WL, Chang FL, Tsai HR, He MS. Diabetes and further risk of cancer: a nationwide population-based study. BMC Med. 2024;22(1):214.","journal-title":"BMC Med"},{"key":"521_CR15","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37:2768\u2013801.","journal-title":"Eur Heart J"},{"key":"521_CR16","doi-asserted-by":"publisher","first-page":"694711","DOI":"10.3389\/fcvm.2021.694711","volume":"8","author":"P Hsu","year":"2021","unstructured":"Hsu P, Mammadova A, Benkirane-Jessel N, Arguel MJ, Hullo M, Laporte S, et al. Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies. Front Cardiovasc Med. 2021;8:694711.","journal-title":"Front Cardiovasc Med"},{"issue":"20","key":"521_CR17","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","volume":"70","author":"H Chang","year":"2017","unstructured":"Chang H, Tochukwu M, Okwuosa D, Tu TY, Asnani A. Best practices in Cardio-Oncology: Part 2. Cardiovascular Complications of Cancer Therapy Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol. 2017;70(20):2552\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"521_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"521_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338.","journal-title":"Lancet Oncol"},{"issue":"10","key":"521_CR20","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.7150\/ijbs.35460","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang H, Wei J, Zheng Q, Meng L, Xin Y, Yin X, et al. Radiation-induced heart disease: a review of classification, mechanism and prevention. Int J Biol Sci. 2019;15(10):2128\u201338.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"521_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11883-019-0810-x","volume":"21","author":"RMFL da Silva","year":"2019","unstructured":"da Silva RMFL. Effects of Radiotherapy in Coronary Artery Disease. Curr Atheroscler Rep. 2019;21(12):50.","journal-title":"Curr Atheroscler Rep"},{"issue":"12","key":"521_CR22","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"9","key":"521_CR23","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447\u201358.","journal-title":"Lancet Oncol"},{"key":"521_CR24","doi-asserted-by":"publisher","first-page":"k3845","DOI":"10.1136\/bmj.k3845","volume":"363","author":"A Matthews","year":"2018","unstructured":"Matthews A, Stanway S, Farmer RE, Strongman H, Thomas S, Lyon AR, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018;363:k3845.","journal-title":"BMJ"},{"issue":"3","key":"521_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/ehjcvp\/pvab005","volume":"8","author":"F Cirne","year":"2022","unstructured":"Cirne F, Aghel N, Petropoulos JA, Hebdon M, Lei L, Guo H, et al. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. Eur Heart J Cardiovasc Pharmacother. 2022;8(3):253\u201362.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"521_CR26","first-page":"e556","volume":"19","author":"KS Virgo","year":"2023","unstructured":"Virgo KS, Shore ND, Antonarakis ES, Dave N, Karsh L, Lynch C, et al. Real-World Cardiovascular Safety Analysis of Apalutamide, Darolutamide, and Enzalutamide in Patients With Advanced Prostate Cancer: A Population-Based Study. JCO Oncol Pract. 2023;19(4):e556\u201365.","journal-title":"JCO Oncol Pract"},{"issue":"41","key":"521_CR27","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"34","key":"521_CR28","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"key":"521_CR29","doi-asserted-by":"publisher","unstructured":"Gynnild MN, Holtrop J, Hageman SHJ, Vinje V, Dorresteijn JAN, Visseren FLJ, Holte E, Dalen H, Wethal T, Omland T. External validation of the systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in cancer patients. Eur J Prev Cardiol. 2026;33(4):500\u2013510. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf356. PMID: 40581371.","DOI":"10.1093\/eurjpc\/zwaf356"},{"issue":"12","key":"521_CR30","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ejhf.1292","volume":"20","author":"N Pareek","year":"2018","unstructured":"Pareek N, Cevallos J, Moliner P, Shah A, Tan LL, Chambers V, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail. 2018;20(12):1721\u201331.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"521_CR31","first-page":"829","volume":"10","author":"MO Mohamed","year":"2021","unstructured":"Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY, et al. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care. 2021;10(8):829\u201339.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"39","key":"521_CR32","first-page":"4420","volume":"44","author":"JP Collet","year":"2023","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(39):4420\u2013534.","journal-title":"Eur Heart J"},{"issue":"36","key":"521_CR33","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u2013537.","journal-title":"Eur Heart J"},{"issue":"3","key":"521_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267\u2013315.","journal-title":"Eur Heart J"},{"issue":"1","key":"521_CR35","first-page":"15","volume":"14","author":"S Sturdy","year":"2023","unstructured":"Sturdy S, Wright P, Mediratta N, Casula R, Santangelo G, Yap J, et al. Tako-tsubo carcinopathy: an increasingly recognised but still incompletely understood association between cancer and stress-induced cardiomyopathy. J Cardiol Curr Res. 2023;14(1):15\u201322.","journal-title":"J Cardiol Curr Res"},{"key":"521_CR36","doi-asserted-by":"publisher","unstructured":"Dafaalla M, Costa F, Kontopantelis E, Araya M, Kinnaird T, Micari A, Jia H, Mintz GS, Mamas MA. Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score. Eur Heart J. 2024;45(34):3138\u20133148. https:\/\/doi.org\/10.1093\/eurheartj\/ehae463. Erratum in: Eur Heart J. 2024;45(38):4140. https:\/\/doi.org\/10.1093\/eurheartj\/ehae581. PMID: 39016180; PMCID: PMC11379492.","DOI":"10.1093\/eurheartj\/ehae463"},{"issue":"11","key":"521_CR37","first-page":"734","volume":"12","author":"E Barbato","year":"2023","unstructured":"Barbato E, B\u00e4r S, Abdel-Wahab M, Andreotti F, Kaifoszova Z, L\u00f8land KH, et al. Management of acute coronary syndromes in patients with thrombocytopenia. Eur Heart J Acute Cardiovasc Care. 2023;12(11):734\u201342.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"4","key":"521_CR38","first-page":"399","volume":"37","author":"J Kanduri","year":"2019","unstructured":"Kanduri J, More LA, Godishala A, Asnani A. Fluoropyrimidine-Associated Cardiotoxicity. Cardiol Clin. 2019;37(4):399\u2013405.","journal-title":"Cardiol Clin"},{"issue":"6","key":"521_CR39","doi-asserted-by":"publisher","first-page":"970","DOI":"10.21037\/jgo.2017.09.07","volume":"8","author":"SC Clasen","year":"2017","unstructured":"Clasen SC, Ky B, O\u2019Quinn R, Giantonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol. 2017;8(6):970\u20139.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"521_CR40","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaccao.2020.06.012","volume":"2","author":"A Padegimas","year":"2020","unstructured":"Padegimas A, Carver JR. How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest Pain: A Single Center Approach. JACC CardioOncol. 2020;2(4):650\u20134.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"521_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.30321","volume":"123","author":"WW Ma","year":"2017","unstructured":"Ma WW, Saif MW, El-Rayes BF, Fakih MG, Cartwright TH, Posey JA, King TR, von Borstel RW, Bamat MK. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017;123(2):345\u201356.","journal-title":"Cancer"},{"issue":"19","key":"521_CR42","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.3390\/jcm10194426","volume":"10","author":"M Jurczyk","year":"2021","unstructured":"Jurczyk M, Kr\u00f3l M, Midro A, Kurnik-\u0141ucka M, Poniatowski A, Gil K. Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. J Clin Med. 2021;10(19):4426.","journal-title":"J Clin Med"},{"issue":"24","key":"521_CR43","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.3390\/cancers15245885","volume":"15","author":"A Pons-Riverola","year":"2023","unstructured":"Pons-Riverola A, Morillas H, Berdejo J, Pernas S, Pomares H, Asiain L, Garay A, Fernandez-Ortega A, Oliveira AC, Mart\u00ednez E, Jim\u00e9nez-Marrero S, Pina E, Fort E, Ramos R, Alcoberro L, Hidalgo E, Antonio-Rebollo M, Alcober L, Enjuanes Grau C, Com\u00edn-Colet J, Moliner P. Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments. Cancers (Basel). 2023;15(24):5885.","journal-title":"Cancers (Basel)"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00521-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:46:24Z","timestamp":1788824784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00521-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00521-y","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}